Clearmind Medicine Gets IRB Approval for Second Clinical Trial Site
Ticker: CMND · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, FDA, biotech
TL;DR
Clearmind Medicine's CMND-100 trial gets green light at a second site, moving closer to FDA approval.
AI Summary
Clearmind Medicine Inc. announced on October 10, 2024, that its Investigational Review Board (IRB) has approved the commencement of its first-in-human clinical trial for CMND-100 at a second clinical site. This trial is designed to evaluate the safety and efficacy of CMND-100, a potential treatment for alcohol use disorder.
Why It Matters
This approval allows Clearmind Medicine to expand its clinical trial, potentially accelerating the development of CMND-100 and bringing a new treatment option for alcohol use disorder closer to market.
Risk Assessment
Risk Level: medium — Clinical trial progress is a key driver for biotech companies, but regulatory approvals and trial outcomes carry inherent risks.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- CMND-100 (drug) — Investigational drug
- October 10, 2024 (date) — Announcement date
FAQ
What is the primary purpose of the CMND-100 clinical trial?
The clinical trial is designed to evaluate the safety and efficacy of CMND-100, a potential treatment for alcohol use disorder.
What specific approval did Clearmind Medicine receive?
Clearmind Medicine received Investigational Review Board (IRB) approval for its first-in-human clinical trial of CMND-100 at a second clinical site.
When was this announcement made?
The announcement was made on October 10, 2024.
What is the significance of the second clinical site approval?
The approval for a second clinical site allows Clearmind Medicine to expand its clinical trial, potentially accelerating the development process.
What form is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 273 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-10-10 16:01:02
Filing Documents
- ea0217297-6k_clear.htm (6-K) — 11KB
- ea021729702ex99-1_clear.htm (EX-99.1) — 14KB
- 0001213900-24-086883.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: October 10, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3